baber/WOPTO huggingface dataset:
Patent NZ-199985-A (NZ)
Title: Antimicrobial triazole derivatives
Inventor: STURM E
IPC: A01N43/653
Filed: 1982-03-11
Abstract: A compound selected from the group consisting of a 2 min -amino-2 min -phenyl-ethyl-1H-1,2,4-triazole of the formula (I) <CHEM> and the phytopharmaceutically acceptable salts and metal complexes thereof, wherein: R1 is a member selected from the group consisting of hydrogen, halo, C1-C4-alkyl, C1-C4-alkyloxy, and C1-C2-haloalkyl; R2 is a member selected from the group consisting of hydrogen, halo, C1-C4-alkyl, C1-C4-alkyloxy, C1-C2-haloalkyl and phenyl; R3 is a member selected from the group consisting of hydrogen, C1-C12-alkyl, C3-C8-cycloalkyl which is optionally substituted with C1-C4-alkyl, and aralkyl with maximum 2 carbon atoms in the alkyl part and optionally substituted on the phenyl nucleus with halo or nitro; R4 is a member selected from the group consisting of hydrogen and C1-C4-alkyl; whereby R3 and R4 may, together with the nitrogen atom to which they are attached, form a 3- to 7-membered saturated heterocyclic ring which may optionally be interrupted by oxygen, sulfur or NR5 and optionally substituted with R6, wherein R5 and R6 are each independently C1-C4-alkyl, a method of combating microorganisms by the use of such compounds, microbicidal agents comprising such compounds as active ingredients, processes of preparing the subject compounds and intermediates used therefore.
Patent NZ-202955-A (NZ)
Title: Azolyl-thioether derivatives and fungicidal compositions
Inventor: REGEL E
IPC: C07D249/08
Filed: 1983-01-06
Abstract: Compound which are azolyl-thioether derivatives of the general formula    <IMAGE>  (I)  in which A represents a nitrogen atom or a CH group, B represents a CO or CH(OH) group, m is 0 or 2, R1 represents an optionally substituted phenyl radical and R2 represents an optionally substituted cycloalkyl radical or a grouping of the general formula   <IMAGE>  wherein X and Y are identical or different and represent a hydrogen or halogen atom, Z represent an alkyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylthio, optionally substituted benzyloxy, optionally substituted benzylthio, alkoxy, alkylthio, halogenoalkoxy, halogenoalkylthio, alkoxycar-onyl or cyano radical, and n is 0 or 1, and the acid addition salts and metal salt complexes thereof, are novel and prepared by several processes described and find use as fungicides and as agents for regulating plant growth.
Patent NZ-208259-A (NZ)
Title: Production of recombinant baculovirus expression vectors
Inventor: SMITH G E
IPC: C12N15/62
Filed: 1984-05-23
Abstract: A method for producing a recombinant baculovirus expression vector, capable of expressing a selected gene in a host insect cell, is disclosed. The method involves cleaving baculovirus DNA to produce a DNA fragment comprising a polyhedrin gene or portion thereof, including a polyhedrin promoter. A recombinant transfer vector is prepared by inserting said DNA fragment into a cloning vehicle and there-after inserting a selected gene into the thus modified cloning vehicle such that it is under the transcriptional control of the polyhedrin promoter. The recombinant transfer fector is contacted with a baculovirus DNA so as to effect recombination and incorporation of the selected gene into the baculovirus genome. The resultant recombinant baculovirus is then used to infect susceptible insects or cultured insect cells and the protein product from the incorporated selected gene is produced from the infection.
Patent NZ-227843-A (NZ)
Title: Compositions for darkening hair
Inventor: WILKINS A L
IPC: A61K8/33
Filed: 1989-02-02
Abstract: A composition for darkening hair comprises a first component, which comprises a shampoo detergent base and at least one metal salt; and a second component which comprises at least one organic compound which, in use changes colour as a consequence of the formation of a dark-coloured complex when mixed with the said metal ion, and a base suitable for use as a hair shampoo, conditioner, tonic, cream, styling gel or mousse such compositions being presented as a multi- compartment device or kit.
Patent NZ-229904-A (NZ)
Title: Preparation of acetic acid and acetic anhydride
Inventor: ERPENBACH HEINZ
IPC: C07C51/12
Filed: 1989-07-11
Abstract: For the preparation of acetic acid and acetic anhydride, methanol and methyl acetate are reacted under anhydrous conditions with carbon monoxide in the presence of a carbonyl complex of group VIII noble metals, methyl iodide, and catalyst systems containing alkali metal or quaternary organophosphonium or organoammonium acetate or iodide. The hot carbonylation mixture is depressurised, the evaporated components are added to a first distillation zone, and the remaining catalyst solution is fed back to the reaction zone. In the first distillation zone, the volatile carbonylation products are fractionally distilled; the low-boiling components methyl iodide and methyl acetate pass back into the reaction zone, and a mixture of acetic acid and acetic anhydride is obtained as a bottom product which is separated into the pure components in a second and third distillation zone.
Patent NZ-243472-A (NZ)
Title: SUBSTITUTED 7H-PYRAZOLO [4,3-d] PYRIMIDIN-7-ONE DERIVATIVES, PREPARATION AND
Inventor: BELL ANDREW SIMON
IPC: A61P27/14
Filed: 1992-07-08
Abstract: Compounds of formula: <CHEM>  and pharmaceutically acceptable salts thereof,  wherein R<1> is H; C1-C3 alkyl optionally substituted with one or more fluoro substituents; or C3-C5 cycloalkyl; R<2> is H, or C1-C6 alkyl optionally susbtituted with one or more fluoro subtituents or with C3-C6 cycloalkyl; R<3> is C1-C6 alkyl optionally substituted with one or more fluoro substituents or with C3-C6 cycloalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R<4> is C1-C4 alkyl optionally substituted with OH, NR<5>R<6>, CN, CONR<5>R<6> or CO2R<7>; C2-C4 alkenyl optionally substituted with CN, CONR<5>R<6> or CO2R<7>; C2-C4 alkanoyl optionally substituted with NR<5>R<6>; hydroxy C2-C4 alkyl optionally susbtituted with NR<5>R<6>; (C2-C3 alkoxy)C1-C2 alkyl optionally substituted with OH or NR<5>R<6>; CONR<5>R<6>; CO2R<7>; halo; NR<5>R<6>; NHSO2NR<5>R<6>; NHSO2R<8>; or phenyl or heterocyclyl either of which is optionally substituted with methyl; R<5> and R<6> are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached from a pyrrolidinyl, piperidino, morpholino, 4-(NR<9>)-piperazinyl or imidazoyl group wherein said group is optionally substituted with methyl or hydroxy; R<7> is H or C1-C4 alkyl; R<8> is C1-C3 alkyl optionally substituted with NR<5>R<6>; and R<9> is H; C1-C3 alkyl optionally substituted with phenyl; hydroxy C2-C3 alkyl; or C1-C4 alkanoyl; are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
Patent NZ-244779-A (NZ)
Title: 2,3-dihydro-2h-imidazo[4,5-b]quinolin-2-one derivatives and pharmaceutical compositions
Inventor: FREYNE EDDY JEAN EDGARD
IPC: C07D401/12
Filed: 1992-10-16
Abstract: Novel 1,3-dihydro-2H-imidazoÄ4,5-bÜquinolin-2-one derivatives of formula <CHEM> wherein R is hydrogen, C<5> PI 1/4 alkyl, C<7> PI 1/4 cycloalkyl, phenyl optionally substituted with from 1 to 3 substituents each independently selected from halo, hydroxy, C<5> PI 1/4 alkyloxy, C psi  PI 1/4 cycloalkyloxy, C<5> PI 1/4 alkyl or trifluoromethyl; pyridinyl; thienyl optionally substituted with halo or C<5> PI 1/4 alkyl; and     +C=X is a radical of formula    +C=O   (a),    +C=N-O-R<1>   (b), or    +C=CH-R<2>   (c);   the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, said compounds being potent inhibitors of both phosphodiesterase III and IV, which are useful in the treatment of allergic disorders, atopic diseases and related afflictions. Intermediates in the preparation thereof. Pharmaceutical compositions containing said compounds as an active ingredient. Methods of preparing said compounds and pharmaceutical compositions.
Patent NZ-247787-A (NZ)
Title: Di-substituted phenyl piperazine and piperidine derivatives, medicaments, and precursors
Inventor: BAXTER ELLEN W
IPC: A61K31/495
Filed: 1993-06-03
Abstract: Compounds of the general formula I: <CHEM> are disclosed as potent antipsychotic agents. Novel methods of use and intermediates used to make the compounds of formula I are also disclosed.
Patent NZ-287641-A (NZ)
Title: Modular wall block system comprises a grid-like sheet having multiple strands extending rearwardly held to wall blocks by a connector device consisting of a cross-bar and fingers
Inventor: MILLER ROBERT A
IPC: E02D29/02
Filed: 1995-05-22
Abstract: A modular wall block is formed with a trough or recess in a top surface configured to frictionally receive fingers of a rake-like grid connection device. The fingers are engaged through apertures in an end portion of a grid-like sheet of material with the spine of the rake overlying the grid-like sheet of material, the remainder of the grid-like sheet of material extending rearwardly to reinforce the fill behind a retaining wall formed from a plurality of courses of the wall blocks. Slat members are selectively received in one of a pair of grooves defined in each side of the wall blocks with portions of the slats extending above the upper surface of the block to contact a surface of an opening formed in a superimposed block for positioning the front faces of the blocks in the retaining wall relative to each other in either a vertically aligned or rearwardly offset relationship. The slats also include portions projecting laterally from the sides of the block and spanning the space between adjacent blocks in a course of blocks to position juxtaposed blocks in each course relative to each other. Alternatively, the rake includes, in addition to fingers projecting downwardly from the spine, tabs projecting upwardly from the spine. The tabs engage a slot in a bottom of the wall block for positioning, depending upon the direction of extension of the tabs, the front faces of the blocks in the retaining wall relative to each other in either a vertically aligned or vertically offset relationship.
Patent NZ-318939-A (NZ)
Title: Neurturin and related growth factors
Inventor: JOHNSON EUGENE M
IPC: A61P25/16
Filed: 1996-08-27
Abstract: A novel growth factor, neurturin, is disclosed and the human and mouse amino acid sequences are identified. Human and mouse neurturin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. The subcloning into vectors and the preparation of cells stably transformed with the vectors are also disclosed. In addition, methods for treating degenerative conditions, tumor cells and obesity; methods for detecting gene alterations and methods for detecting and monitoring patient levels of neurturin are provided. Methods for identifying additional members of the neurturin-GDNF family of growth factors are also provided.
Patent NZ-329348-A (NZ)
Title: Expression and amplification of an endogenous gene by homologous recombination
Inventor: TRECO DOUGLAS A
IPC: A61K38/43
Filed: 1997-12-08
Abstract: Method of activating expression of and amplifying an endogenous gene in genomic DNA of a vertebrate cell which is not expressed in the cell as obtained or is not expressed at significant levels in the cell as obtained, comprising the steps of: (a) transfecting cells with DNA sequences comprising: 1) exogenous DNA sequences which repair, alter, delete or replace a sequence present in the cell or which are regulatory sequences not normally functionally linked to the endogenous gene in the cell as obtained; 2) DNA sequences homologous with genomic DNA sequences at a preselected site in the cells; and 3) amplifiable DNA encoding a selectable marker; (b) maintaining the cells under conditions appropriate for homologous recombination to occur between DNA sequences homologous with genomic DNA sequences and genomic DNA sequences; (c) culturing the homologously recombinant cells produced in (b) under conditions which select from amplification of the amplifiable DNA encoding a selectable marker, whereby the amplifiable DNA encoding a selectable marker and the endogenous gene functionally linked to exogenous DNA of (a) 1) are coamplified.
Patent NZ-333188-A (NZ)
Title: Use of DNA scaffold attachments regions to modify expression of a heterologous gene
Inventor: AGARWAL MANJU
IPC: C12N15/68
Filed: 1997-06-06
Abstract: Provided is the use of scaffold attachment regions (SARs) to increase gene expression in primary no-proliferating cells or resting cells, particular in transduced eukaryotic resting primary cells, especially retrovirally transduced cells.  The SAR sequence is reported to have no detectable influence on retroviral vector expression in transduced cell lines.  Specifically claimed is a retroviral vector comprising genetic material corresponding to (a) at least one SAR, and (b) at least one heterologous gene operatively linked to an expression control sequence, the heterologous gene (or at least one if there are more than one heterologous gene) being rev-M10 and the SAR or at least one SAR is derived from, obtainable from or corresponds to the 5' SAR of the human interferon-b gene, as well as claiming cellular compositions comprising non-immortal human cells transduced with the retroviral vector, particularly hematopoietic cells like T cells.  The retroviral vector can be used to prepare compositions for the treatment of HIV infection.
Patent NZ-336248-A (NZ)
Title: Sulfonyl urea derivatives particularly relates to aryl and heteroaryl and their use in the control of interleukin-1 activity for treatment of inflammation in joints, central nervous system, gastrointestinal tract, endocardium, pericardium, lung, eyes, ears, skin and urogenital system
Inventor: DOMBROSKI MARK ANTHONY
IPC: A61P29/00
Filed: 1997-12-29
Abstract: A compound of formula (I) wherein R1 and R2 substituents are as defined in the description, R2 being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumours which produce IL-1 as an autocrine growth factor, cachexia, Alzheimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.  Wherein;  R1 and R2 are each independently a group of the formula (II), (III), (IV), (V), (VI) and (VII).
Patent NZ-336284-A (NZ)
Title: Positive flow valve for controlling flow between medical implement and catheter tip with seal increasing or decreasing in size when moved between two positions
Inventor: LOPEZ GEORGE A
IPC: A61M5/00
Filed: 1997-12-15
Abstract: A closed system, spikeless, positive-flow valve device includes a body defining an internal cavity. At the proximal end of the body is an opening which is preferably sufficiently large to receive an ANSI standard tip of a medical implement. The valve includes a plastic, resilient silicon seal which fills the upper cavity and opening with an oval seal cap having a slit. The opening presses the oval seal cap to keep the slit closed in the decompressed state. The slit opens as the nose of the medical implement compresses the seal into the cavity and the seal cap is free from the opening. The housing also includes a fluid space which facilitates fluid flow between the medical implement and a catheter tip. The fluid space within the valve automatically and reversibly increases upon insertion of the medical implement into the cavity and decreases upon withdrawal of the medical implement, such that a positive flow from the valve toward the catheter tip is effected upon withdrawal of the medical implement, thereby preventing a flow of blood from a patient into the catheter when the medical implement is removed from the valve.
Patent NZ-336812-A (NZ)
Title: Luer connector with screw connection to enable sharpened end to be driven through closure to enter vial
Inventor: THILLY JACQUES
IPC: A61J1/20
Filed: 1998-01-16
Abstract: A luer connector has: a luer connectable to a syringe and which extends to a sharpened end capable of being driven through a puncturable vial closure to thereby puncture the closure; a luer support, mountable on a vial, and which initially supports the luer in a first position in which the sharpened end of the conduit is pointed toward the closure; a luer driver such that movement of the driver relative to the support causes the luer to be driven so that the sharpened end punctures the closure and enters the vial. The luer connector facilitates connection of a hypodermic syringe to the vial.
Patent NZ-501197-A (NZ)
Title: Stable dentrifice comprising sodium bicarbonate and plant extracts
Inventor: XU JIN
IPC: A61K8/97
Filed: 1999-02-26
Abstract: The oral health care formulation comprises: a) at least 35 wt% of sodium bicarbonate; b) 1 to 5 wt% of a blend of natural ingredients which have a tendency to separate or undergo synersis with sodium bicarbonate; c) up to 5 wt% if a flavoring oil and d) a combination of at least one binder, at least one surfactant and at least one humectant wherein the combination of the at least one binder, at least one surfactant and at least one humectant makes the formulation stable to degradation and resistant to synersis.
Patent NZ-503785-A (NZ)
Title: Dofetilide polymorphs
Inventor: APPLEBY IAN COLIN
IPC: C07C311/08
Filed: 1998-10-09
Abstract: Substantially pure, crystalline, dofetilide polymorph P162 which is characterised by differential scaning calorimetry (DSC) in which it exhibits an endothermic thermal event at about 162oC. A process for the abovementioned polymorph is also disclosed. A pharmaceutical formulation containing dofetilide polymorph P162 is disclosed. Dofetilide polymorph P162 can be used to treat a variety of diseases such as arrythmias and congestive heart failure.
Patent NZ-503975-A (NZ)
Title: A multi-channel fibre grating using a repetitive structure in which repeated envelopes are imposed on a higher frequency component
Inventor: LAMING RICHARD IAN
IPC: G02B6/34
Filed: 1998-10-23
Abstract: An optical fibre waveguide with a section which is modulated in refractive index so as to form a grating with a plurality of characteristic reflection wavelength channels, in which the refractive index modulation comprises an amplitude modulation having: a) an underlying higher frequency component defining the shape of the reflection profile of each of the wavelength channels; b) a lower frequency component imposing repeated envelopes over the higher frequency component and defining the separation of the wavelength channels, the envelope shape of the lower frequency component being such as to impart a substantially even response to each of the wavelength channels and to limit the plurality of wavelength channels to a finite number thereof and c) discrete substantially pi phase shifts at least between the envelopes of the lower frequency component.
Patent NZ-504566-A (NZ)
Title: The amorphous form of zafirulkast (Form A), a leukotriene antagonist, as a pharmaceutical composition in a multi-layered sustained release formulation for treatment of asthma and related conditions
Inventor: CORVARI SUSAN JANE
IPC: A61P43/00
Filed: 1998-12-15
Abstract: A dry powder layering process for preparing pharmaceutical compositions of the leukotriene antagonist zafirlukast is described.  The process forms coated beads suitable for sprinkling on to food and drink.  Each pellet comprises: a)  a core; b)  a first layer surrounding the core which contains amorphous zafirlukast substantially free of other physical forms; and c)  a second coating layer which does not contain zafirlukast; each layer optionally comprising other pharmaceutically acceptable ingredients.
Patent NZ-504847-A (NZ)
Title: Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
Inventor: GREGORY RICHARD J
IPC: C07K14/47
Filed: 1998-12-04
Abstract: Recombinant nucleic acid molecules encoding a chimeric transactivator protein are described.  The chimeric transactivator protein includes a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation.  Also provided are recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivor proteins in mammalian cells.  Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. A schematic of the adenoviral sequences contained within the HIF-lá/VP16 adenoviral vectors is shown. This vector is identical to the Ad2CMVBgal-6 backbone except that the B-gal gene has been replaced with the HIF-lá/VP16 hybrid construct.
Patent NZ-506347-A (NZ)
Title: Methods of producing intraocular lenses and materials suitable for their production
Inventor: HODD KENNETH A
IPC: A61F2/16
Filed: 1999-03-16
Abstract: An  ophthalmically acceptable aqueous solution capable of  producing  an  elastically deformable  intraocular  lens having   a  refractive  index  of  at  least  1.39   and   a sufficiently low viscosity to be injectable in the  capsular bag  of  the eye with a conventional cannula, said  solution comprising water soluble macromolecular particles of a  size sufficiently  small to provide an optically clear  solution, and  wherein  the  macromolecular particles  have  molecular weights  of  at  least 50,000 Daltons and diameters  in  the range of about 5 to 160 nm.
Patent NZ-509832-A (NZ)
Title: New oral formulation for 5-HT4 agonists or antagonists
Inventor: DE BRUIJN KAREL
IPC: C07D209/14
Filed: 1999-08-19
Abstract: A solid pharmaceutical composition comprising the compound (3-(5-methoxy-1H-indol-3-yl-methylene)-N- pentylcarbazimidamide), of formula (A), or its salts, and a disintegrant that is present in an amount of at least 15% by weight based on the total weight of the composition. The composition is used in the manufacture of a medicament for the treatment of gastro-intestinal motility disorders in horses or cattle.
Patent NZ-514178-A (NZ)
Title: Veneer dehydrating apparatus comprising a pair of roll assemblies with tooth-like projections and deformable elastic sections
Inventor: KOBA YOSHINORI
IPC: B27D1/00
Filed: 2001-09-13
Abstract: Described is a veneer dehydrating apparatus which has a pair of rotatable dehydrating roll assemblies disposed one above the other and having their axes extending parallel to each other, at least one of which is positively driven.  The paired roll assemblies include a first roll assembly having formed on the peripheral surface thereof a number of tooth-like projections extending radially outward from the peripheral surface and a second roll assembly having a steel core shaft which is clad with a covering of elastic material such as urethane rubber with a predetermined thickness. The axes of the roll assemblies are spaced radially to form a clearance or a nip between the peripheral surfaces thereof which is smaller than the thickness of the veneer sheet to be dehydrated.  The second roll assembly has formed therein a number of annular grooves spaced axially of the second roll assembly at an interval of 50 mm or less and each having a width of 10 mm or less, thereby having a number of sectional elastic portions which are separated by any two adjacent annular grooves and each of such elastic portions being deformable independently of other similar portions.